| Bioactivity | Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH)[1][2]. |
| Invitro | Mipomersen (800 和 1000 μg/mL；72 小时) 可降低 HCVcc (JFH1) 感染的 Huh7/CD81 WT细胞中 80%-85% 的胞内 HCV RNA[2]。 |
| In Vivo | Mipomersen (25 mg/kg；腹腔注射，每周 2 次，共 11 周) 影响 h-apoB，h-apoB-100，Lp(a) 和 OxPL/h-apoB 的水平[1]。 Animal Model: |
| Name | Mipomersen |
| CAS | 1000120-98-8 |
| Molar Mass | 7177.00 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Merki E, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation. 2008 Aug 12;118(7):743-53. [2]. Schaefer EA, et al. Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C. World J Gastroenterol. 2016 Dec 7;22(45):9954-9965. |